Patents by Inventor Eric Lorent

Eric Lorent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20260152549
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: November 12, 2025
    Publication date: June 4, 2026
    Applicants: Ablynx NV, Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • Polypeptides comprising immunoglobulin single variable domains targeting TNF? and IL-23
    Patent number: 12528860
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: January 20, 2026
    Assignees: Ablynx NV, Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • Polypeptides comprising immunoglobulin single variable domains targeting il-13 and OX40L
    Patent number: 12509522
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: December 30, 2025
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Klaus Erb, Eric Lorent, John Park, Robert Resnick, Melanie Rieger, Bernd Weigle
  • Methods of treatment utilizing polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
    Patent number: 12492248
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: December 9, 2025
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • Nucleic acids encoding polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
    Patent number: 12384840
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: August 12, 2025
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF ALPHA
    Publication number: 20240301049
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 28, 2023
    Publication date: September 12, 2024
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Nadine Biesemann, Ann Brige, Sigrid Cornelis, Karen Heyninck, Eric Lorent, Shanna Van Zwam
  • CX3CR1-BINDING COMPOUNDS, METHODS AND USES THEREOF
    Publication number: 20240117038
    Abstract: The present technology relates to a polypeptide comprising at least three immunoglobulin single variable domains (ISVDs). In particular, the present technology relates to a polypeptide comprising an optimized ISVD binding to fractalkine receptor CX3CR1 and an optimized ISVD binding to albumin. The present technology also relates to a composition of a polypeptide; a polynucleotide encoding a polypeptide; a host or host cell comprising a polynucleotide; a method for producing a polypeptide or composition; and a polypeptide, polynucleotide or composition for use in prevention, therapy and diagnosis of a disease or disorder.
    Type: Application
    Filed: July 18, 2023
    Publication date: April 11, 2024
    Applicants: Ablynx N.V., Sanofi
    Inventors: Judith Verhelst, Paolo Meoni, Eric Lorent
  • Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-?
    Patent number: 11897951
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: February 13, 2024
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Nadine Biesemann, Ann Brigé, Sigrid Cornelis, Karen Heyninck, Eric Lorent, Shanna Van Zwam
  • Methods of treating asthma with polypeptides targeting IL-13 and TSLP
    Patent number: 11840566
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: December 12, 2023
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND IL-23
    Publication number: 20220372128
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: April 25, 2022
    Publication date: November 24, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND IL-23
    Publication number: 20220363747
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: April 25, 2022
    Publication date: November 17, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF-a
    Publication number: 20220356241
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 17, 2021
    Publication date: November 10, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Nadine Biesemann, Ann Brigé, Sigrid Cornelis, Karen Heyninck, Eric Lorent, Shanna Van Zwam
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20220177565
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20220177566
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20220177564
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND OX40L
    Publication number: 20220153854
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: September 24, 2021
    Publication date: May 19, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Klaus Erb, Eric Lorent, John Park, Robert Resnick, Melanie Rieger, Bernd Weigle
  • Polypeptides comprising immunoglobulin single variable domains targeting TNFA and IL-23
    Patent number: 11332525
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: May 17, 2022
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND IL-23
    Publication number: 20220064281
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: October 15, 2021
    Publication date: March 3, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
    Patent number: 11208476
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: December 28, 2021
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20210214431
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: March 22, 2021
    Publication date: July 15, 2021
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernhard Weigle, Klaus Erb